Purdue’s confirmed Plan of Reorganization (“Plan”) was vacated on appeal by the United States District Court for the Southern District of New York. Purdue is appealing the ruling while simultaneously continuing its efforts to forge yet further consensus around a Plan that will deliver billions of dollars to the American people for opioid abatement. The District Court decision does not affect Purdue’s operational stability or its ability to produce its many medications safely and effectively. We continue to operate fully, honoring our existing relationships and meeting our obligations to our partners, customers, and consumers. The company continues serving patients and consumers who rely on its medicines and products, pursuing its pipeline, and introducing medicines that will help save and improve lives.
Our Commitment to Safety as we Navigate Coronavirus
We have always been guided by our core values—Collaboration, Integrity, Courage, and Innovation—but now, facing the challenges posed by COVID-19, our core values have taken on new meaning. The health and safety of our colleagues, customers and community, along with the continuity of business operations – critical to serve patients who rely on our medicines and products – are our top priorities.
Our manufacturing facilities are open and operating but, where our workforce can work from home, they are doing so. We have taken special measures to protect those who continue to work on-site during this time, including enhanced cleaning, shift adjustments, social distancing, and business continuity planning, among other measures.
Our business remains open. Our products are available, and we have not identified any supply chain risks at this time. We continue to progress our public health initiatives and our pipeline. Please continue to contact us through your normal channels. Our medical team is available and if you have questions related to our products please contact us; 1-888-726-7535; www.AskPurdueMedical.com. Other contact information can be found here.
We are particularly concerned that the pandemic is triggering indirect health risks for people with (or those at risk of experiencing) substance use disorders. Through our office of Corporate Social Responsibility, Purdue is providing $500,000 in additional monetary support to local and national organizations focused on the pandemic, as well as those delivering harm reduction programs, improving access to medication-assisted treatment, and supporting continuity of recovery services during the pandemic.
We are confident that, by facing new challenges through a data-driven, health-conscious, and business continuity-focused lens, we can continue to serve those who rely on our medicines and products.
With a dedicated team and a robust pipeline of novel therapy candidates, we work to develop important new medicines that can meaningfully improve the lives of patients around the world.
About Us
Imbrium is a clinical-stage biopharmaceutical company dedicated to advancing medical science through the development of important new therapeutics.
Imbrium is dedicated to collaborating with commercial and academic partners to advance novel therapies that address unmet patient need. We welcome the opportunity to learn about new drug development programs and technologies in the areas of CNS, oncology chemotherapeutics, and non-opioid pain. Please reach us at partnering@54.163.211.251 .
